TOKYO – Despite being home to world-class biomedical research and large innovative drug and device companies, a lack of an entrepreneurial ecosystem has emerged as a significant challenge for the biotech and med-tech industries. That is a challenge that regulators are now trying to address and overcome.
TOKYO – Despite being home to world-class biomedical research and large innovative drug and device companies, a lack of an entrepreneurial ecosystem has emerged as a significant challenge for the biotech and med-tech industries. That is a challenge that regulators are now trying to address and overcome.
TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) is looking to play an active role in achieving "rational medicine" in the country, the idea that a patient-centric system should optimize care from the patient's point of view based on the latest scientific knowledge.
TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) is looking to play an active role in achieving "rational medicine" in the country, the idea that a patient-centric system should optimize care from the patient's point of view based on the latest scientific knowledge.
TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib. The deal grants Takeda exclusive commercial and further clinical development rights in Japan for cabozantinib.
TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib. The deal grants Takeda exclusive commercial and further clinical development rights in Japan for cabozantinib.
TOKYO – Japan’s pharmaceutical industry is calling for a more collaborative relationship between government and industry in the face of uncertainties in the country and the possibility of more frequent reviews of drug prices.
TOKYO – Japan's pharmaceutical industry is calling for a more collaborative relationship between government and industry in the face of uncertainties in the country and the possibility of more frequent reviews of drug prices.
TOKYO – The stocks of Japan's biopharmaceutical companies have taken a hit since U.S. President Donald Trump said, almost two weeks ago, that pharma companies have been "getting away with murder." Unlike their U.S. counterparts, Japanese stocks have not recovered from that significant broadside.
